Sera Prognostics (SERA) reported second-quarter 2026 revenue of $30,000, compared with $17,000 in the prior-year quarter. Net loss was $9.1 million, compared with $8.0 million for the second quarter of 2025.
The company said it ended the quarter with approximately $80.3 million in cash, cash equivalents and available-for-sale securities, which it believes will fund operations through significant adoption and commercialization milestones through 2029.
- Second-quarter operating expenses were $10.0 million, compared with $9.3 million a year earlier.
- Research and development expenses were $3.5 million, compared with $3.3 million in the prior-year period.
- Selling, general and administrative expenses were $6.5 million, compared with $6.0 million a year earlier.
- Sera launched its fourth partnership program in August 2026 and said payer discussions span more than 20 opportunities across over 20 states.
- Illinois enacted legislation requiring Medicaid coverage and reimbursement for prescribed proteomic blood tests used to identify spontaneous preterm birth risk and associated interventions.
- The company said pre-application activities for European CE marking are expected to begin in the third quarter, with submission expected to conclude in the fourth quarter of 2026.
$SERA Insider Trading Activity
$SERA insiders have traded $SERA stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $SERA stock by insiders over the last 6 months:
- ZHENYA LINDGARDT (Chief Executive Officer) has made 0 purchases and 4 sales selling 53,357 shares for an estimated $106,299.
- AUSTIN AERTS (Chief Financial Officer) has made 0 purchases and 5 sales selling 15,239 shares for an estimated $30,340.
- ROBERT GARDNER HARRISON (Chief Information Officer) has made 0 purchases and 3 sales selling 6,076 shares for an estimated $12,726.
- BENJAMIN JACKSON (General Counsel) has made 0 purchases and 3 sales selling 6,325 shares for an estimated $12,588.
- DYAARL LEE JR. ANDERSON (Chief Commercial Officer) sold 4,739 shares for an estimated $9,525
- JOHN J. BONIFACE (Chief Scientific Officer) has made 0 purchases and 2 sales selling 4,555 shares for an estimated $9,049.
- PAUL KEARNEY (Chief Data Officer) has made 0 purchases and 2 sales selling 3,422 shares for an estimated $6,818.
- SANDRA AJ LAWRENCE has made 0 purchases and 2 sales selling 3,120 shares for an estimated $6,396.
- TIFFANY EUL DAVIS INGLIS (Chief Medical Officer) sold 362 shares for an estimated $727
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SERA Hedge Fund Activity
We have seen 11 institutional investors add shares of $SERA stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PSP RESEARCH LLC removed 2,396,685 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,361,966
- CITADEL ADVISORS LLC removed 458,705 shares (-64.8%) from their portfolio in Q1 2026, for an estimated $931,171
- SANDERS MORRIS HARRIS LLC removed 314,950 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $573,209
- ABERDEEN GROUP PLC added 202,750 shares (+7.9%) to their portfolio in Q2 2026, for an estimated $369,005
- WHETSTONE CAPITAL ADVISORS, LLC removed 152,824 shares (-4.4%) from their portfolio in Q1 2026, for an estimated $310,232
- GSA CAPITAL PARTNERS LLP removed 107,235 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $195,167
- SEGALL BRYANT & HAMILL, LLC removed 100,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $182,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
